STCube

STCube EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of STCube (052020.KQ) as of Oct 25, 2026 is -26.01 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -20.21 % — a change of 28.72% (lower).

EBIT/Assets

-26.01 %

YoY

28.72%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of STCube is 2025 -26.01 % . Operating Income to Assets Ratio (EBIT/Assets) of STCube was 2024 -20.21 % . It decreases by 28.72% lower compared to the previous year.

The STCube EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-18.39 KRW
Jan 1, 2019
-18.48 KRW
Jan 1, 2020
-24.92 KRW
Jan 1, 2021
-73.28 KRW
Jan 1, 2022
-31.04 KRW
Jan 1, 2023
-56.66 KRW
Jan 1, 2024
-20.21 KRW
Jan 1, 2025
-26.01 KRW
The STCube EBIT/Assets history
YEAREBIT/AssetsYoY
-26.01 %+28.72%
-20.21 %-64.33%
-56.66 %+82.53%
-31.04 %-57.64%
-73.28 %+194.11%
-24.92 %+34.79%
-18.48 %+0.53%
-18.39 %-66.07%
-54.19 %+844.55%
-5.74 %-69.56%
-18.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Operating Income to Assets Ratio (EBIT/Assets) of STCube is -26.01 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of STCube changed from -20.21 % to -26.01 %, representing a 28.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) STCube since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — STCube

All Key Metrics — STCube